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Melanoma cutis is virtually incurable when it has metas-
tasized to distant organs. Unfortunately, there is no safe
and effective adjuvant treatment available for early stage
patients that may prevent the development of metastasis.
Since early melanoma development is accompanied by
impaired immune effector functions in the sentinel
lymph node (SLN), there is a strong rationale for thera-
peutic immune modulation of the SLN aimed at
strengthening cellular immune functions. In two placebo
controlled trials, the immunological effects of i.d. admin-
istration of CpG type-B (PF-3512676, 1 or 8 mg) ± GM-
CSF (Leukine, 100 mg) at the tumor site, one week before
SLN excision, were investigated. The trials showed that
this treatment is clinically safe and flow cytometric and
functional analyses of viable immune effector cells iso-
lated from the SLN showed increased frequencies and
activation state of LN resident CD141+ cDC subsets as
well as activation of pDC and CD1a+ skin derived cDC
subsets in the treated groups. This DC activation was
accompanied by an increased Th1 cytokine response pro-
file and melanoma-specific CD8+ T cell reactivity. Inter-
estingly, when combining the treated groups of both
studies (n=31), we found remarkable clinical differences
compared to the combined placebo groups (n=22).
Important predictors for recurrence and SLN tumor
positivity are Breslow depth and ulceration of the pri-
mary tumor. These two clinical parameters were higher
(although not significantly so) in the treated group.
Nevertheless, the number of tumor positive SLN in this
group was significantly lower (3/31 vs. 8/22 p=0.02). At a
median follow-up of 71 months we also found a longer
recurrence free survival in the treated group (p=0.14).
We conclude that local administration of CpG ± GM-
CSF is safe, shows very promising immunological efficacy
with evidence for clinical impact on lymphatic spread
and recurrence free survival and could potentially be
used as adjuvant treatment combined with primary exci-
sion of suspected melanoma lesions.
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